Sign In
13 Oct 2009 12:51
13 October 2009
Consort Medical plc
Announcement of Directorate Change
Consort Medical plc (LSE: CSRT) announces today that Corporate Development Director Paul Boughton will be leaving the company effective 31st December 2009. Paul was appointed as an Executive Director in June 2006, having served as Corporate Development Director since August 2005.
Commenting on the change, Jon Glenn, CEO, said: "On behalf of the Board I would like to thank Paul for his considerable contribution as a key member of the management team over the past four years."
For further information, please contact:
|
Consort Medical plc |
|
|
Jonathan Glenn, Chief Executive |
Tel: +44 (0) 1442 867920 |
|
Toby Woolrych, Group Finance Director |
Tel: +44 (0) 1442 867920 |
|
Brunswick |
|
|
Jon Coles/Justine McIlroy |
Tel: +44 (0) 20 7404 5959 |
Consort Medical plc is a leader in medical devices for inhaled drug delivery and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.
Consort Medical develops and manufactures metered dose inhaler valves, actuators, compliance aids, dry powder devices, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King's Lynn and Hemel Hempstead in the UK, Indianapolis, Indiana and Kent, Ohio in the US, and Mumbai, India. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).
Follow the stocks
